NASD
| Health Care |
Biotechnology
Purple Biotech Ltd. (PPBT)
LAST (9 Jun)
After-Hours (16:35:43 ET)
MARKET CAP
VOLUME
| Open | 2.58 |
| Previous Close | 2.615 |
| Day Range | 2.54 - 2.73 |
| 52-Week Range | 2.00 - 13.95 |
| All-Time High | 1,390.00 |
| Avg. Volume (50-day) | 129,229.94 |
| EPS (TTM) | -2.45 |
| Next Earnings Date | - |
| Last Earnings Date | - |
| Forward Annual Dividend (Yield) | - |
| Trailing Annual Dividend (Yield) | - |
| Options | Yes |
| P/E Ratio | -1.07 |
| PEG Ratio | - |
| Price to Book | 0.21 |
| Price to Cash Flow | - |
| Price to Free Cash Flow | - |
| Total Sales (TTM) | - |
| Revenue per Share (TTM) | - |
| Shares Outstanding | 2.780 M |
| Share Float (%) | 2.76 M |
| % Held by Institutions | 1.82 |
| Dividends Per Share (TTM) | - |
| Ex-Dividend Date | - |
| +/- EMA(20) | 2.52 (+3.57%) |
| +/- SMA(50) | 2.5 (+4.40%) |
| +/- SMA(200) | 3.86 (-32.38%) |
| 5-Day Perf. | -2.61% |
| 1-Month Perf. | +18.37% |
| 3-Month Perf. | -7.12% |
| 6-Month Perf. | -39.02% |
| YTD Perf. | -44.35% |
| 1-Year Perf. | -77.19% |
| RSI(14) | 56.33 |
| ATR(14) | 0.2 |
| ADX(14) | 12.32 |
| Beta (5Y) | 0.73 |
FOR STOCKCHARTS MEMBERS ONLY
Unlock earnings and revenue history when you join StockCharts
As a StockCharts Member, you can review earnings results and analyze revenue and earnings growth over time. Bring a balance of technicals and fundamentals to your approach when you join today!
PPBT
Purple Biotech Ltd.
Sector: Health Care
Industry: Biotechnology
Employees: 9
Description
Purple Biotech Ltd. is a clinical-stage company, which engages in developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The oncology pipeline includes CM24, NT219, and CAPTN-3. The CM24 is a humanized monoclonal antibody that blocks CEACAM1, which supports tumor immune evasion and survival through multiple pathways. The NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3. The CAPTN-3, a preclinical platform of conditionally activated tri-specific antibodies, which engage both T cells and NK cells to induce a strong, localized immune response within the tumor microenvironment. The company was founded by John Paul Waymack on August 12, 1968 and is headquartered in Rehovot, Israel.
PPBT has triggered the following predefined scans:
| No Recent Scan Appearances |
FOR STOCKCHARTS MEMBERS ONLY
Unlock custom technical alerts when you join StockCharts
As a StockCharts Member, you can create your own unique alerts with the technical criteria that matters most to you. Stay ahead of important moves and never miss a thing in the markets.
FOR STOCKCHARTS MEMBERS ONLY
Unlock ChartLists to save and organize your charts when you join StockCharts
As a StockCharts Member, you can save the charts you're watching to your own account with ChartLists. Accessible from any device, you can organize, review and analyze your charts on-the-go, anytime, anywhere.
